Savara (NASDAQ:SVRA) Sees Strong Trading Volume – Time to Buy?

Savara Inc. (NASDAQ:SVRA) saw an uptick in trading volume on Wednesday. 4,789,849 shares changed hands during trading, an increase of 170% from the average daily volume of 1,774,836 shares. The stock last traded at $5.1050 and had previously closed at $4.92.

Analyst Ratings Changes

SVRA has been the topic of a number of research analyst reports. Royal Bank Of Canada set a $10.00 price target on Savara in a research note on Wednesday, October 7th. Citigroup reaffirmed a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. JPMorgan Chase & Co. started coverage on shares of Savara in a report on Wednesday, October 7th. They set an “overweight” rating and a $12.00 price objective on the stock. Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Thursday, October 15th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and an average price target of $10.25.

Savara Trading Up 3.4%

The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -8.79 and a beta of 0.32. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. The business has a fifty day moving average price of $4.97 and a 200 day moving average price of $5.35.

Savara (NASDAQ:SVRA) last issued its earnings results on Monday, November 9th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01. As a group, equities analysts forecast that Savara Inc. will post -0.66 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Savara during the 2nd quarter worth about $76,966,000. Nantahala Capital Management LLC purchased a new position in Savara in the second quarter valued at approximately $42,977,150. Spruce Street Capital LP purchased a new position in Savara in the second quarter valued at approximately $21,267,868. Nan Fung Trinity HK Ltd. raised its holdings in Savara by 1,088.3% in the third quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock valued at $9,507,000 after buying an additional 1,687,310 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in Savara during the second quarter valued at approximately $8,645,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.